NASDAQ:APLS - Apellis Pharmaceuticals Stock Price, Price Target & More

$24.51 +0.30 (+1.24 %)
(As of 04/20/2018 04:00 PM ET)
Previous Close$24.51
Today's Range$24.05 - $24.78
52-Week Range$12.45 - $32.00
Volume325,177 shs
Average Volume165,731 shs
Market Capitalization$1.33 billion
P/E Ratio-6.68
Dividend YieldN/A
BetaN/A

About Apellis Pharmaceuticals (NASDAQ:APLS)

Apellis Pharmaceuticals logoApellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutic compounds for autoimmune and inflammatory diseases. Its lead product candidate is APL-2 to treat geographic atrophy, wet age-related macular degeneration, paroxysmal nocturnal hemoglobinuria, autoimmune hemolytic anemia, and nephrology. The company develops APL-2 for intravitreal injection that is an injection into the eye, as well as subcutaneous injection, which is an injection into the tissue under the skin. It also develops APL-9 for intravenous administration in systemic indications, which is in single ascending dose Phase I clinical trial. Apellis Pharmaceuticals, Inc. was founded in 2009 and is headquartered in Crestwood, Kentucky.

Receive APLS News and Ratings via Email

Sign-up to receive the latest news and ratings for APLS and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:APLS
CUSIPN/A
Phone502-241-4114

Debt

Debt-to-Equity Ratio0.18%
Current Ratio27.79%
Quick Ratio27.79%

Price-To-Earnings

Trailing P/E Ratio-6.68
Forward P/E Ratio-21.13
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$2.96 per share
Price / Book8.28

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on EquityN/A
Return on AssetsN/A

Miscellaneous

Employees39
Outstanding Shares50,370,000

How to Become a New Pot Stock Millionaire

Apellis Pharmaceuticals (NASDAQ:APLS) Frequently Asked Questions

What is Apellis Pharmaceuticals' stock symbol?

Apellis Pharmaceuticals trades on the NASDAQ under the ticker symbol "APLS."

How were Apellis Pharmaceuticals' earnings last quarter?

Apellis Pharmaceuticals (NASDAQ:APLS) posted its quarterly earnings results on Monday, March, 19th. The company reported ($0.60) EPS for the quarter, missing analysts' consensus estimates of ($0.27) by $0.33. View Apellis Pharmaceuticals' Earnings History.

What price target have analysts set for APLS?

4 brokerages have issued 1 year price objectives for Apellis Pharmaceuticals' stock. Their forecasts range from $23.00 to $35.00. On average, they anticipate Apellis Pharmaceuticals' share price to reach $28.3333 in the next year. View Analyst Ratings for Apellis Pharmaceuticals.

Who are some of Apellis Pharmaceuticals' key competitors?

Who are Apellis Pharmaceuticals' key executives?

Apellis Pharmaceuticals' management team includes the folowing people:
  • Dr. Cedric Francois M.D., Ph.D., Co-Founder, Pres, CEO & Director (Age 46)
  • Dr. Pascal Deschatelets Ph.D., Co-Founder & COO (Age 48)
  • Mr. David O. Watson Esq., J.D., Gen. Counsel & VP of Corp. Devel. (Age 45)
  • Dr. Federico Grossi M.D., Ph.D., Co-Founder & Sr. VP of Clinical Devel. (Age 44)
  • Mr. Alec Machiels J.D., MBA, Co-Founder & Director (Age 45)

When did Apellis Pharmaceuticals IPO?

(APLS) raised $150 million in an initial public offering (IPO) on Thursday, November 9th 2017. The company issued 10,700,000 shares at $13.00-$15.00 per share. Citigroup, J.P. Morgan and Evercore ISI served as the underwriters for the IPO.

When does the company's lock-up period expire?

Apellis Pharmaceuticals' lock-up period expires on Tuesday, May 8th. Apellis Pharmaceuticals had issued 10,714,000 shares in its IPO on November 9th. The total size of the offering was $149,996,000 based on an initial share price of $14.00. Shares of the company owned by company insiders and major shareholders will be eligible for trade following the expiration of the lock-up period.

Has Apellis Pharmaceuticals been receiving favorable news coverage?

News articles about APLS stock have been trending somewhat negative recently, Accern Sentiment reports. The research firm ranks the sentiment of news coverage by reviewing more than 20 million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Apellis Pharmaceuticals earned a coverage optimism score of -0.01 on Accern's scale. They also assigned news articles about the company an impact score of 47.80 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the near future.

How do I buy shares of Apellis Pharmaceuticals?

Shares of APLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Apellis Pharmaceuticals' stock price today?

One share of APLS stock can currently be purchased for approximately $24.51.

How big of a company is Apellis Pharmaceuticals?

Apellis Pharmaceuticals has a market capitalization of $1.33 billion. The company earns $-51,000,000.00 in net income (profit) each year or ($3.67) on an earnings per share basis. Apellis Pharmaceuticals employs 39 workers across the globe.

How can I contact Apellis Pharmaceuticals?

Apellis Pharmaceuticals' mailing address is 6400 WESTWIND WAY SUITE A, CRESTWOOD KY, 40014. The company can be reached via phone at 502-241-4114 or via email at [email protected]


MarketBeat Community Rating for Apellis Pharmaceuticals (APLS)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  43 (Vote Outperform)
Underperform Votes:  30 (Vote Underperform)
Total Votes:  73
MarketBeat's community ratings are surveys of what our community members think about Apellis Pharmaceuticals and other stocks. Vote "Outperform" if you believe APLS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe APLS will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Apellis Pharmaceuticals (NASDAQ:APLS) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
4 Wall Street analysts have issued ratings and price targets for Apellis Pharmaceuticals in the last 12 months. Their average twelve-month price target is $28.3333, suggesting that the stock has a possible upside of 15.60%. The high price target for APLS is $35.00 and the low price target for APLS is $23.00. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyN/A
Consensus Rating Score: 2.753.003.00N/A
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $28.3333$27.00$27.00N/A
Price Target Upside: 15.60% upside78.93% upside92.58% upsideN/A

Apellis Pharmaceuticals (NASDAQ:APLS) Consensus Price Target History

Price Target History for Apellis Pharmaceuticals (NASDAQ:APLS)

Apellis Pharmaceuticals (NASDAQ:APLS) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/12/2018B. RileyDowngradeBuy -> Neutral$27.00HighView Rating Details
3/23/2018JPMorgan ChaseBoost Price TargetOverweight -> Overweight$31.00 -> $35.00LowView Rating Details
12/4/2017Evercore ISIInitiated CoverageOutperformHighView Rating Details
12/4/2017CitigroupInitiated CoverageBuy$23.00HighView Rating Details
(Data available from 4/20/2016 forward)

Earnings

Apellis Pharmaceuticals (NASDAQ:APLS) Earnings History and Estimates Chart

Earnings by Quarter for Apellis Pharmaceuticals (NASDAQ:APLS)

Apellis Pharmaceuticals (NASDAQ:APLS) Earnings Estimates

Current Year EPS Consensus Estimate: $-1.16 EPS
Next Year EPS Consensus Estimate: $-1.45 EPS

Apellis Pharmaceuticals (NASDAQ APLS) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
3/19/2018Q4 2017($0.27)($0.60)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Apellis Pharmaceuticals (NASDAQ:APLS) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Apellis Pharmaceuticals (NASDAQ APLS) Insider Trading and Institutional Ownership History

Institutional Ownership Percentage: 31.26%
Insider Trading History for Apellis Pharmaceuticals (NASDAQ:APLS)
Insider Trading History for Apellis Pharmaceuticals (NASDAQ:APLS)

Apellis Pharmaceuticals (NASDAQ APLS) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
11/13/2017Global Strategic Fund I VenbioMajor ShareholderBuy127,515$14.00$1,785,210.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Apellis Pharmaceuticals (NASDAQ APLS) News Headlines

Source:
DateHeadline
Apellis sets price for second offering that could raise more than $140MApellis sets price for second offering that could raise more than $140M
finance.yahoo.com - April 19 at 4:37 PM
Apellis prices stock offering at $25.50; shares down 1% premarketApellis prices stock offering at $25.50; shares down 1% premarket
seekingalpha.com - April 19 at 9:29 AM
Here's a more complete picture of Apellis' executive compensationHere's a more complete picture of Apellis' executive compensation
finance.yahoo.com - April 18 at 9:30 AM
Why GoPro, Apellis Pharmaceuticals, and Hertz Global Holdings Slumped TodayWhy GoPro, Apellis Pharmaceuticals, and Hertz Global Holdings Slumped Today
finance.yahoo.com - April 17 at 4:51 PM
 Analysts Anticipate Apellis Pharmaceuticals (APLS) to Announce -$0.27 Earnings Per Share Analysts Anticipate Apellis Pharmaceuticals (APLS) to Announce -$0.27 Earnings Per Share
www.americanbankingnews.com - April 17 at 11:15 AM
Apellis Pharma readies stock offeringApellis Pharma readies stock offering
seekingalpha.com - April 17 at 9:50 AM
Apellis Pharmaceuticals Announces Proposed Offering of Common StockApellis Pharmaceuticals Announces Proposed Offering of Common Stock
finance.yahoo.com - April 17 at 9:50 AM
Louisville company to raise $125 million through stock offeringLouisville company to raise $125 million through stock offering
finance.yahoo.com - April 17 at 9:50 AM
 Apellis Pharmaceuticals (APLS) Given Average Recommendation of "Strong Buy" by Brokerages Apellis Pharmaceuticals (APLS) Given Average Recommendation of "Strong Buy" by Brokerages
www.americanbankingnews.com - April 13 at 3:29 AM
Apellis Pharmaceuticals (APLS) Downgraded by B. Riley to NeutralApellis Pharmaceuticals (APLS) Downgraded by B. Riley to Neutral
www.americanbankingnews.com - April 12 at 11:17 AM
In The Spotlight: Apellis PharmaIn The Spotlight: Apellis Pharma
www.nasdaq.com - April 12 at 10:23 AM
Heres how much Apellis executives will make in 2018Here's how much Apellis executives will make in 2018
www.bizjournals.com - April 4 at 5:05 PM
Apellis Pharmaceuticals (APLS) Upgraded by Zacks Investment Research to BuyApellis Pharmaceuticals (APLS) Upgraded by Zacks Investment Research to Buy
www.americanbankingnews.com - April 2 at 4:46 PM
Zacks: Brokerages Anticipate Apellis Pharmaceuticals (APLS) Will Announce Earnings of -$0.27 Per ShareZacks: Brokerages Anticipate Apellis Pharmaceuticals (APLS) Will Announce Earnings of -$0.27 Per Share
www.americanbankingnews.com - March 31 at 1:23 PM
 Apellis Pharmaceuticals (APLS) Receives Consensus Recommendation of "Strong Buy" from Brokerages Apellis Pharmaceuticals (APLS) Receives Consensus Recommendation of "Strong Buy" from Brokerages
www.americanbankingnews.com - March 29 at 10:28 AM
Apellis Pharmaceuticals (APLS) Rating Lowered to Hold at Zacks Investment ResearchApellis Pharmaceuticals (APLS) Rating Lowered to Hold at Zacks Investment Research
www.americanbankingnews.com - March 28 at 5:28 PM
Apellis Pharmaceuticals (APLS) Upgraded to Buy by Zacks Investment ResearchApellis Pharmaceuticals (APLS) Upgraded to Buy by Zacks Investment Research
www.americanbankingnews.com - March 27 at 5:44 PM
JPMorgan Chase & Co. Raises Apellis Pharmaceuticals (APLS) Price Target to $35.00JPMorgan Chase & Co. Raises Apellis Pharmaceuticals (APLS) Price Target to $35.00
www.americanbankingnews.com - March 23 at 4:00 PM
Apellis Pharmaceuticals Inc Expected to Earn FY2018 Earnings of ($1.06) Per Share (APLS)Apellis Pharmaceuticals Inc Expected to Earn FY2018 Earnings of ($1.06) Per Share (APLS)
www.americanbankingnews.com - March 22 at 11:20 AM
Apellis reports millions in losses in first annual filing — but that’s OKApellis reports millions in losses in first annual filing — but that’s OK
finance.yahoo.com - March 22 at 9:45 AM
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial ResultsApellis Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results
finance.yahoo.com - March 20 at 9:43 AM
Zacks: Apellis Pharmaceuticals Inc (APLS) Given $32.50 Consensus Target Price by BrokeragesZacks: Apellis Pharmaceuticals Inc (APLS) Given $32.50 Consensus Target Price by Brokerages
www.americanbankingnews.com - March 14 at 7:30 PM
Financial Comparison: Vericel (VCEL) and Apellis Pharmaceuticals (APLS)Financial Comparison: Vericel (VCEL) and Apellis Pharmaceuticals (APLS)
www.americanbankingnews.com - March 12 at 3:10 AM
Analysts Expect Apellis Pharmaceuticals Inc (APLS) to Announce ($0.27) Earnings Per ShareAnalysts Expect Apellis Pharmaceuticals Inc (APLS) to Announce ($0.27) Earnings Per Share
www.americanbankingnews.com - March 8 at 9:29 PM
Contrasting Apellis Pharmaceuticals (APLS) and Its RivalsContrasting Apellis Pharmaceuticals (APLS) and Its Rivals
www.americanbankingnews.com - March 6 at 3:21 PM
Sectoral Asset Management Inc Purchases New Position in Apellis Pharmaceuticals Inc (APLS)Sectoral Asset Management Inc Purchases New Position in Apellis Pharmaceuticals Inc (APLS)
www.americanbankingnews.com - March 5 at 3:33 PM
Zacks: Apellis Pharmaceuticals Inc (APLS) Given $32.50 Consensus Target Price by AnalystsZacks: Apellis Pharmaceuticals Inc (APLS) Given $32.50 Consensus Target Price by Analysts
www.americanbankingnews.com - March 3 at 5:28 AM
Zacks: Analysts Anticipate Apellis Pharmaceuticals Inc (APLS) Will Post Earnings of -$0.27 Per ShareZacks: Analysts Anticipate Apellis Pharmaceuticals Inc (APLS) Will Post Earnings of -$0.27 Per Share
www.americanbankingnews.com - February 25 at 11:58 AM
Comparing Apellis Pharmaceuticals (APLS) and Its CompetitorsComparing Apellis Pharmaceuticals (APLS) and Its Competitors
www.americanbankingnews.com - February 25 at 3:16 AM
Opiant Pharmaceuticals (OPNT) & Apellis Pharmaceuticals (APLS) Critical ContrastOpiant Pharmaceuticals (OPNT) & Apellis Pharmaceuticals (APLS) Critical Contrast
www.americanbankingnews.com - February 24 at 1:36 PM
Financial Analysis: Apellis Pharmaceuticals (APLS) versus Its PeersFinancial Analysis: Apellis Pharmaceuticals (APLS) versus Its Peers
www.americanbankingnews.com - February 24 at 1:36 PM
Apellis Pharmaceuticals to Participate in Upcoming Investor ConferencesApellis Pharmaceuticals to Participate in Upcoming Investor Conferences
finance.yahoo.com - February 23 at 9:25 AM
Critical Contrast: Argos Therapeutics (ARGS) & Apellis Pharmaceuticals (APLS)Critical Contrast: Argos Therapeutics (ARGS) & Apellis Pharmaceuticals (APLS)
www.americanbankingnews.com - February 21 at 3:20 PM
Contrasting Apellis Pharmaceuticals (APLS) and Its PeersContrasting Apellis Pharmaceuticals (APLS) and Its Peers
www.americanbankingnews.com - February 18 at 11:08 PM
Kadmon (KDMN) & Apellis Pharmaceuticals (APLS) Critical ComparisonKadmon (KDMN) & Apellis Pharmaceuticals (APLS) Critical Comparison
www.americanbankingnews.com - February 18 at 7:02 PM
Financial Review: Apellis Pharmaceuticals (APLS) and Its RivalsFinancial Review: Apellis Pharmaceuticals (APLS) and Its Rivals
www.americanbankingnews.com - February 18 at 5:14 PM
Apellis Pharmaceuticals (APLS) and Its Peers Financial ContrastApellis Pharmaceuticals (APLS) and Its Peers Financial Contrast
www.americanbankingnews.com - February 17 at 7:32 PM
Zacks: Apellis Pharmaceuticals Inc (APLS) Given $32.50 Average Target Price by AnalystsZacks: Apellis Pharmaceuticals Inc (APLS) Given $32.50 Average Target Price by Analysts
www.americanbankingnews.com - February 13 at 1:44 PM
Apellis Pharmaceuticals Inc (APLS) Forecasted to Post FY2017 Earnings of ($0.51) Per ShareApellis Pharmaceuticals Inc (APLS) Forecasted to Post FY2017 Earnings of ($0.51) Per Share
www.americanbankingnews.com - February 12 at 1:08 AM
Apellis Pharmaceuticals (APLS) Earns Buy Rating from Analysts at B. RileyApellis Pharmaceuticals (APLS) Earns Buy Rating from Analysts at B. Riley
www.americanbankingnews.com - February 11 at 3:24 PM
Zacks: Apellis Pharmaceuticals Inc (APLS) Given Consensus Rating of "Strong Buy" by AnalystsZacks: Apellis Pharmaceuticals Inc (APLS) Given Consensus Rating of "Strong Buy" by Analysts
www.americanbankingnews.com - February 9 at 9:28 PM
 Brokerages Anticipate Apellis Pharmaceuticals Inc (APLS) Will Post Earnings of -$0.27 Per Share Brokerages Anticipate Apellis Pharmaceuticals Inc (APLS) Will Post Earnings of -$0.27 Per Share
www.americanbankingnews.com - February 8 at 7:20 PM
Apellis Pharmaceuticals, Inc. (APLS) Sees Large Increase in Short InterestApellis Pharmaceuticals, Inc. (APLS) Sees Large Increase in Short Interest
www.americanbankingnews.com - January 12 at 2:38 AM
Apellis Pharmaceuticals to Present at the 36th Annual J.P. Morgan Healthcare ConferenceApellis Pharmaceuticals to Present at the 36th Annual J.P. Morgan Healthcare Conference
finance.yahoo.com - January 2 at 8:19 AM
Apellis Pharmaceuticals (APLS) Says It Finalized Phase 3 Clinical Trial Plans for Geographic Atrophy Treatment with APL-2Apellis Pharmaceuticals (APLS) Says It Finalized Phase 3 Clinical Trial Plans for Geographic Atrophy Treatment with APL-2
www.streetinsider.com - December 21 at 6:29 PM
Louisvilles newest public company has a new CFOLouisville's newest public company has a new CFO
www.bizjournals.com - December 20 at 6:20 PM
Apellis Finalizes Phase 3 Clinical Trial Plans for Geographic Atrophy Treatment with APL-2Apellis Finalizes Phase 3 Clinical Trial Plans for Geographic Atrophy Treatment with APL-2
finance.yahoo.com - December 20 at 6:20 PM
Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) to Ring The Nasdaq Stock Market Closing BellApellis Pharmaceuticals, Inc. (Nasdaq: APLS) to Ring The Nasdaq Stock Market Closing Bell
feeds.benzinga.com - December 13 at 10:55 AM
Apellis Pharmaceuticals IncApellis Pharmaceuticals Inc
www.bloomberg.com - December 13 at 8:15 AM
Apellis Pharmaceuticals, Inc.s (APLS) Quiet Period Set To End  on December 19thApellis Pharmaceuticals, Inc.'s (APLS) Quiet Period Set To End on December 19th
www.americanbankingnews.com - December 12 at 1:22 AM

SEC Filings

Apellis Pharmaceuticals (NASDAQ:APLS) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Apellis Pharmaceuticals (NASDAQ:APLS) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Apellis Pharmaceuticals (NASDAQ APLS) Stock Chart for Friday, April, 20, 2018

Loading chart…

This page was last updated on 4/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.